Table 5 Effect of bedaquiline use for the treatment of DR-TB on incidence, prevalence and mortality in 5-year increments between 2020 and 2040 in China
Cumulative reduction (%, absolute) | Change in each five-year period | Change over the period 2020–2040 | ||||
|---|---|---|---|---|---|---|
2020–2025 | 2025–2030 | 2030–2035 | 2035–2040 | |||
Incidence | No bedaquiline | 8% | 7% | 6% | 6% | 30% |
Bedaquiline use; 61% success rate | 1% | 2% | 2% | 3% | 8% | |
Bedaquiline use; 80% success rate | −6% | −3% | −2% | −1% | −12% | |
Prevalence | No bedaquiline | 5% | 4% | 4% | 4% | 19% |
Bedaquiline use; 61% success rate | −7% | −4% | −2% | 0% | −12% | |
Bedaquiline use; 80% success rate | −19% | −13% | −8% | −4% | −38% | |
Mortality | No bedaquiline | 7% | 6% | 5% | 5% | 26% |
Bedaquiline use; 61% success rate | −16% | −5% | −1% | −0% | −21% | |
Bedaquiline use; 80% success rate | −40% | −20% | −11% | −6% | −60% | |